Neurotech International Ltd. ( (AU:NTI) ) has issued an update.
Neurotech International Ltd has received a positive opinion from the European Medicines Agency for Orphan Medicinal Product Designation of NTI164 for treating Rett Syndrome, a rare neurological disorder affecting approximately 28,000 females in Europe. This follows a similar designation by the US FDA, positioning NTI164 for market entry in both the US and Europe, potentially benefiting from regulatory advantages such as market exclusivity and fee reductions.
More about Neurotech International Ltd.
Neurotech International Limited is a clinical-stage biopharmaceutical development company focused on pediatric neurological disorders. The company is developing NTI164, a broad-spectrum oral cannabinoid drug therapy, and has conducted clinical trials in Autism Spectrum Disorder, PANDAS/PANS, and Rett Syndrome. Neurotech is also exploring treatments for spastic cerebral palsy.
YTD Price Performance: -36.67%
Average Trading Volume: 546,985
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$39.6M
For detailed information about NTI stock, go to TipRanks’ Stock Analysis page.